Dacomitinib

(Vizimpro®)

Dacomitinib

Drug updated on 5/17/2024

Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Dacomitinib (Vizimpro) is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. It has shown promising efficacy in patients with major uncommon EGFR mutations and specific subtypes, demonstrating significant internal heterogeneity in response among these patient groups. Additionally, it exhibits an encouraging intracranial tumor control ability.
  • A comprehensive analysis was conducted on seven systematic reviews/meta-analyses related to Vizimpro's use for treating NSCLC. These studies provided insights into its effectiveness and safety profile across different populations and compared to other treatments.
  • In a network meta-analysis comparing various treatment regimens within the Asian population, Dacomitinib showed good survival benefits measured by median PFS/OS and had a lower risk of adverse events alongside drugs like Furmonertinib, Osimertinib, and Aumolertinib.
  • For patients without brain metastasis, Dacomitinib demonstrated superior efficacy compared to standard care but did not top the list when considering those with brain metastases where combinations like Osimertinib plus Bevacizumab were more effective.
  • Despite showing no significant overall survival benefits over standard chemotherapy treatments among Asian patients carrying either exon 19 deletion or L858R mutation; Erlotinib plus Bevacizumab, Ramucirumab plus Erlotinib along with Dacomitinib consistently showed better progression-free survival benefits.
  • The application of PARP inhibitor combined with Dacomitinib led to notable progression-free survival (PFS) and overall survival (OS), suggesting potential utility as follow-up treatment strategies post-resistance to first-choice TKIs such as Osimertinib-resistant brain leptomeningeal metastases according to case studies reviewed.

Product Monograph / Prescribing Information

Document TitleYearSource
Vizimpro (dacomitinib) Prescribing Information.2020Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib. 2023Translational Cancer Research
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.2023Frontiers in Pharmacology
Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.2023Chinese Medical Journal
Overall survival benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review and network meta-analysis.2022Cancers
Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis.2022JTO Clinical Research and Reports
Olaparib combined with dacomitinib in osimertinib-resistant brain and leptomeningeal metastases from non-small cell lung cancer: a case report and systematic review.2022Frontiers in Oncology
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.2019British Medical Journal

Clinical Practice Guidelines